Search - tctmd.com

Displaying 361 - 380 of 458

Sort: Relevancy | Date

Presentation

A Phase 2 Placebo-Controlled Trial Demonstrating Reversal of Rivaroxaban-induced Anticoagulation

Presenter: Mark Crowther

December 22, 2013

News Daily News

Apixaban es Similar a Warfarin en Pacientes con FA sometidos a Cardioversión

December 05, 2013

News Daily News

Apixaban Comparable to Warfarin for A-fib Patients Undergoing Cardioversion

December 05, 2013

Presentation TCT 2013

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Presenter: C. Michael Gibson

October 31, 2013

Presentation TCT 2013

Case Presentation: A Patient With Atrial Fibrillation on Rivaroxaban Who Develops a STEMI

Presenter: E. Magnus Ohman

October 31, 2013

News Conference News ESC 2013

ESC Congress 2013: Mix of Trials with Potential to Reshape Practice

September 09, 2013

News Conference News ESC 2013

New Alternatives Match Efficacy to Warfarin in High-Risk Subgroups

Caitlin E. Cox

September 03, 2013

News Conference News ESC 2013

Pooled Trial, Registry Data Support Watchman for Stroke Prevention in A-fib

Yael L. Maxwell

September 02, 2013

News Conference News ESC 2013

Novel Anticoagulant Edoxaban Surpasses Warfarin Across Spectrum of VTE Patients

Caitlin E. Cox

September 02, 2013

News Daily News

For A-fib Patients, Aspirin on Top of Anticoagulation Raises Bleeding Risk

Caitlin E. Cox

July 25, 2013

News Daily News

En Pacientes con FA, Aspirina + Anticoagulación Aumenta el Riesgo Hemorrágico

Caitlin E. Cox

July 25, 2013

News Daily News

Después de un accidente cerebrovascular menor/AIT, la terapia antiplaquetaria doble reduce el accidente cerebrovascular recurrente en comparación con la aspirina

July 24, 2013

News Daily News

After Minor Stroke/TIA, Dual Antiplatelet Therapy Reduces Recurrent Stroke vs. Aspirin

July 24, 2013

News Daily News

El Apixaban No es Inferior a la Terapia Estándar en el Tratamiento de los Tromboembolismos Venosos Agudos

L.A. McKeown

July 05, 2013

News Daily News

Apixaban Noninferior to Standard Therapy for Acute Venous Thromboembolism

L.A. McKeown

July 05, 2013

News Daily News

ROCKET AF: La Insuficiencia Cardíaca No Resta Validez del Rivaroxaban

Caitlin E. Cox

June 20, 2013

News Daily News

ROCKET AF: Heart Failure Does Not Weaken the Case for Rivaroxaban

Caitlin E. Cox

June 20, 2013

Presentation

Efficacy and Safety of Rivaroxaban in Patients with Heart Failure and Nonvalvular A-Efficacy and Safety of Rivaroxaban in Patients with Heart Failure and Nonvalvular A-fibfib

Presenter: Sean van Diepen

June 10, 2013

News Daily News

Novel Anticoagulants Cost-Effective vs. Warfarin in A-fib Patients

Caitlin E. Cox

May 13, 2013

News Daily News

El Apixaban Superior a la Warfarin con independencia del Tipo y Duración de la FA

May 13, 2013

Advertisement

A Phase 2 Placebo-Controlled Trial Demonstrating Reversal of Rivaroxaban-induced Anticoagulation

Apixaban es Similar a Warfarin en Pacientes con FA sometidos a Cardioversión

Apixaban Comparable to Warfarin for A-fib Patients Undergoing Cardioversion

Potential for Rivaroxaban Use in ACS and in the PCI Patient: Why Different Interpretations of the Same Data in the US and Europe?

Case Presentation: A Patient With Atrial Fibrillation on Rivaroxaban Who Develops a STEMI

ESC Congress 2013: Mix of Trials with Potential to Reshape Practice

New Alternatives Match Efficacy to Warfarin in High-Risk Subgroups

Pooled Trial, Registry Data Support Watchman for Stroke Prevention in A-fib

Novel Anticoagulant Edoxaban Surpasses Warfarin Across Spectrum of VTE Patients

For A-fib Patients, Aspirin on Top of Anticoagulation Raises Bleeding Risk

En Pacientes con FA, Aspirina + Anticoagulación Aumenta el Riesgo Hemorrágico

Después de un accidente cerebrovascular menor/AIT, la terapia antiplaquetaria doble reduce el accidente cerebrovascular recurrente en comparación con la aspirina

After Minor Stroke/TIA, Dual Antiplatelet Therapy Reduces Recurrent Stroke vs. Aspirin

El Apixaban No es Inferior a la Terapia Estándar en el Tratamiento de los Tromboembolismos Venosos Agudos

Apixaban Noninferior to Standard Therapy for Acute Venous Thromboembolism

ROCKET AF: La Insuficiencia Cardíaca No Resta Validez del Rivaroxaban

ROCKET AF: Heart Failure Does Not Weaken the Case for Rivaroxaban

Efficacy and Safety of Rivaroxaban in Patients with Heart Failure and Nonvalvular A-Efficacy and Safety of Rivaroxaban in Patients with Heart Failure and Nonvalvular A-fibfib

Novel Anticoagulants Cost-Effective vs. Warfarin in A-fib Patients

El Apixaban Superior a la Warfarin con independencia del Tipo y Duración de la FA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content